TransCode Therapeutics says Australia accepts patent application for siRNA cancer nanoparticle delivery

Bitget2026/09/22 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

TransCode Therapeutics reported patent progress in Australia, citing acceptance of an application covering siRNA cancer therapies using nanoparticle delivery.
Japan granted a patent covering RNA immunomodulatory compositions designed to activate innate immune pathways such as RIG-I in tumors.
Australian application covers iron-oxide, dextran-coated nanoparticles with covalently linked siRNA, spanning broad oncology use.
Japanese claims include approaches aimed at cancers expressing miR-21, including nanoparticle-enabled delivery systems.
Australian patent, if granted, is expected to expire on Sept. 6, 2039.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220804PR_NEWS_USPR_____NE53047) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

TransCode Therapeutics says Australia accepts patent application for siRNA cancer nanoparticle delivery

You may also like

Crypto prices